Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

PROK

ProKidney Corp

Nov 07 • 04:00PM ET

2.89

+0.08 2.85 %

Healthcare • Biotechnology • USA • NASD

Peers: FMS DVA OPK NEPH RMTI AKBA MNKD ARDX ADMA PDEX

| Held by: VXF SCHA SCHB MSSM

Index	-	P/E	-	EPS (ttm)	-0.56	Insider Own	27.57%	Shs Outstand	133.42M	Perf Week	-5.56%
Market Cap	850.48M	Forward P/E	-	EPS next Y	-0.52	Insider Trans	-0.13%	Shs Float	97.78M	Perf Month	-12.42%
Enterprise Value	1.90B	PEG	-	EPS next Q	-0.13	Inst Own	30.13%	Short Float	10.98%	Perf Quarter	28.16%
Income	-72.47M	P/S	1604.68	EPS this Y	18.45%	Inst Trans	-8.94%	Short Ratio	5.11	Perf Half Y	300.61%
Sales	0.53M	P/B	-	EPS next Y	-2.14%	ROA	-16.64%	Short Interest	10.74M	Perf YTD	71.01%
Book/sh	-7.51	P/C	2.89	EPS next 5Y	10.44%	ROE	-	52W High	7.13 -59.47%	Perf Year	78.40%
Cash/sh	1.00	P/FCF	-	EPS past 3/5Y	11.32% -	ROIC	-	52W Low	0.46 527.85%	Perf 3Y	-72.42%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-927.51%	Volatility	10.46% 8.44%	Perf 5Y	-
Dividend TTM	-	EV/Sales	3588.91	EPS Y/Y TTM	4.97%	Oper. Margin	-33456.74%	ATR (14)	0.25	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	11.48	Sales Y/Y TTM	-	Profit Margin	-13752.18%	RSI (14)	48.10	Recom	2.17
Dividend Gr. 3/5Y	- -	Current Ratio	11.48	EPS Q/Q	23.18%	SMA20	-5.17%	Beta	1.82	Target Price	5.40
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	3.70%	Rel Volume	0.98	Prev Close	2.81
Employees	204	LT Debt/Eq	-	Earnings	Aug 12 AMC	SMA200	59.39%	Avg Volume	2.10M	Price	2.89
IPO	Jun 30, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	10.03% -	Trades		Volume	2,054,351	Change	2.85%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-30-25	Downgrade	BofA Securities	Neutral → Underperform	$1
Sep-30-24	Initiated	JP Morgan	Neutral
Sep-10-24	Initiated	Guggenheim	Buy	$6
Mar-07-24	Resumed	Morgan Stanley	Equal-Weight	$3
Jan-02-24	Downgrade	BofA Securities	Buy → Neutral
Jul-25-23	Initiated	BTIG Research	Buy	$16
Dec-21-22	Initiated	Jefferies	Buy	$15
Nov-10-22	Initiated	Morgan Stanley	Equal-Weight	$13
Oct-18-22	Initiated	UBS	Buy	$18
Oct-14-22	Initiated	Citigroup	Buy	$16
Sep-23-22	Initiated	BofA Securities	Buy	$14
Sep-02-22	Initiated	Evercore ISI	Outperform

Show Previous Ratings

Nov-06-25 11:00AM	ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025 (GlobeNewswire)
Oct-29-25 07:30AM	ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference (GlobeNewswire)
Oct-20-25 07:30AM	ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2025 (GlobeNewswire) +10.77%
Sep-20-25 02:43AM	ProKidney Corp (PROK) Touts Reparencel Therapy for Growth (Insider Monkey)
Aug-27-25 07:30AM	ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference (GlobeNewswire)
04:01PM	Loading…
Aug-12-25 04:01PM	ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates (GlobeNewswire) +5.80%
Jul-22-25 11:03AM	ProKidney Corp (PROK) Completes Re-domestication to Delaware amid Kidney Therapy Advancement (Insider Monkey) -5.28%
04:52AM	Meet the Biotech Stock That Rocketed 775% Higher (Motley Fool)
Jul-20-25 12:35AM	JP Morgan Maintains a Neutral Stance on ProKidney Corp. (PROK) (Insider Monkey)
Jul-17-25 12:00PM	PROKIDNEY CP (PROK) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks) -5.63%
10:00AM	Best Momentum Stocks to Buy for July 17th (Zacks)
06:40AM	This Biotech Stock Jumped Over 600% in Just Days After Releasing Promising Clinical Trial Data. And Its Market Cap Is Still Only $2 Billion. But Is It a Buy? (Motley Fool)
05:38AM	New Strong Buy Stocks for July 17th (Zacks)
Jul-16-25 12:00PM	ProKidney Corp. (PROK) is a Great Momentum Stock: Should You Buy? (Zacks) +10.68%
Jul-15-25 07:30AM	ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel (GlobeNewswire) -8.67%
09:45AM	Loading…
Jul-14-25 09:45AM	ProKidney Just Set a New 52-Week High. Should You Buy, Sell, or Hold PROK Stock Here? (Barchart) -18.72%
Jul-12-25 07:30AM	'Story' stocks are smoking hot in 2025. This is how it could end badly for investors. (MarketWatch)
Jul-09-25 12:26PM	PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study (Zacks) +16.35%
07:51AM	ProKidney, Meta & EssilorLuxottica, Apple COO: Trending Tickers (Yahoo Finance Video)
07:30AM	ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference (GlobeNewswire)
Jul-08-25 05:09PM	ProKidney's stock rockets on 'intriguing' news, but analyst doesn't recommend buying (MarketWatch) +515.00%
07:00AM	ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and Diabetes (GlobeNewswire)
Jul-01-25 12:43PM	ProKidney Corp. Completes Domestication from the Cayman Islands to Delaware (GlobeNewswire)
Jun-30-25 09:36AM	Circle initiated, Disney upgraded: Wall Street's top analyst calls (The Fly) -11.46%
May-12-25 04:15PM	ProKidney Reports First Quarter 2025 Financial Results and Business Highlights (GlobeNewswire) +15.79%
Mar-21-25 09:55AM	Down -38% in 4 Weeks, Here's Why You Should You Buy the Dip in PROKIDNEY CP (PROK) (Zacks)
Mar-17-25 07:30AM	ProKidney Reports Full Year 2024 Financial Results and Business Highlights (GlobeNewswire) +5.73%
Jan-07-25 07:30AM	ProKidney to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-26-24 07:30AM	ProKidney to Participate in Two Upcoming Conferences: Evercore HealthCONx Conference and the Citi Global Healthcare Conference (GlobeNewswire)
Nov-12-24 07:30AM	ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting (GlobeNewswire)
07:30AM	Loading…
Nov-05-24 07:30AM	ProKidney to Participate in the Guggenheim Inaugural Healthcare Innovation Conference and the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-22-24 07:02PM	Suvretta Capital Management's Strategic Acquisition in ProKidney Corp (GuruFocus.com) -8.11%
Oct-14-24 07:30AM	ProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2024 (GlobeNewswire)
Oct-09-24 07:30AM	ProKidney to Participate in the UBS Virtual Organ Restoration Day (GlobeNewswire)
Sep-04-24 01:33PM	ProKidney drops Phase III CKD study to focus on US market and save up to $175m (Clinical Trials Arena) -9.17%
Sep-03-24 07:30AM	ProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel's Registrational Path to Potential Approval in the U.S. (GlobeNewswire)
Aug-27-24 07:30AM	ProKidney to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire) -7.53%
Aug-09-24 07:00AM	ProKidney Reports Business Updates and Second Quarter 2024 Financial Results (GlobeNewswire)
Jun-27-24 05:52AM	PROK Stock Earnings: ProKidney Reported Results for Q4 2023 (InvestorPlace) +6.61%
Jun-26-24 02:10PM	Hedge Fund and Insider Trading News: Crispin Odey, Boaz Weinstein, Ken Griffin, Greenlight Capital, Eisler Capital, ProKidney Corp (PROK), Essex Property Trust Inc (ESS), and More (Insider Monkey)
Jun-17-24 07:00AM	ProKidney Announces the Closing of $140 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering, Including Exercise of Underwriters' Option (GlobeNewswire) +6.96%
Jun-11-24 09:35PM	ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering (GlobeNewswire) -19.87% +23.55%
07:40AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
Jun-10-24 04:15PM	ProKidney Announces Proposed $125 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering (GlobeNewswire) -5.33%
07:32AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
06:30AM	ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates (GlobeNewswire)
May-29-24 07:00AM	ProKidney to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire) +6.74%
May-21-24 07:00AM	ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024 (GlobeNewswire)
May-10-24 03:43PM	ProKidney Corp Reports First Quarter 2024 Financial Results (GuruFocus.com) +7.66%
01:54PM	PROK Stock Earnings: ProKidney Beats EPS for Q1 2024 (InvestorPlace)
07:48AM	ProKidney Q1 Loss Unchanged From Year Earlier (MT Newswires)
07:00AM	ProKidney Reports Business Updates and First Quarter 2024 Financial Results (GlobeNewswire)
Mar-25-24 06:05AM	ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations (GlobeNewswire)
Mar-21-24 07:49PM	ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire) -6.16%
Feb-29-24 04:05PM	ProKidney to Participate in Jefferies Biotech on the Bay Summit (GlobeNewswire)
Dec-29-23 08:22AM	Chamath Palihapitiya Stocks: 12 Stocks Pumped in the Last 10 Years (Insider Monkey)
Dec-13-23 09:55AM	Here's Why ProKidney Corp. (PROK) Is a Great 'Buy the Bottom' Stock Now (Zacks) +9.60%
Nov-30-23 06:05AM	ProKidney Appoints Nikhil Pereira-Kamath, MBA, as Chief Business Officer (GlobeNewswire) -10.16%
Nov-24-23 06:40AM	7 Penny Stocks With Low Floats and High Short Interest (InvestorPlace)
Nov-21-23 06:05AM	ProKidney to Participate in a Fireside Chat at the Upcoming Evercore ISI 6th Annual HEALTHCONx Conference (GlobeNewswire) +5.68%
Nov-17-23 01:38PM	ProKidney Corp. (NASDAQ:PROK) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-16-23 09:35AM	After Plunging -37.39% in 4 Weeks, Here's Why the Trend Might Reverse for ProKidney Corp. (PROK) (Zacks) -11.51%
Nov-14-23 07:04AM	ProKidney Corp (PROK) Reports Q3 Financial Results: Focus on Chronic Kidney Disease Trials (GuruFocus.com) -5.00%
06:05AM	ProKidney Reports Third Quarter Financial Results (GlobeNewswire)
Nov-13-23 05:02PM	ProKidney Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT ) for Diabetic CKD and Provides Corporate Updates (GlobeNewswire)
Oct-30-23 04:12PM	ProKidney Announces Four Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2023 (GlobeNewswire) +12.29%
Oct-17-23 09:35AM	ProKidney Corp. (PROK) Loses -54.93% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) -7.93%
Oct-16-23 02:50PM	Is Chamath Palihapitiya Giving Up on ProKidney (PROK) Stock? (InvestorPlace)
Oct-12-23 03:05PM	Why Shares of ProKidney Were Dropping Thursday (Motley Fool) -31.45%
Sep-06-23 12:14PM	ProKidney confirms it will expand HQ complex, add 50 jobs in Winston-Salem (American City Business Journals)
Sep-05-23 06:05AM	ProKidney to Participate in Fireside Chat at the Morgan Stanley Global Healthcare Conference (GlobeNewswire)
Aug-31-23 10:33AM	3 Biotech Stocks Due for a Massive Short Squeeze (InvestorPlace)
Aug-29-23 01:16PM	ProKidney confirmed as company seeking incentives to expand in Forsyth County (American City Business Journals)
Aug-11-23 02:21PM	ProKidney reports $38.8 million loss in Q2 FY2023 as it advances clinical trials and prepares for Greensboro manufacturing expansion (American City Business Journals)
Aug-10-23 04:10PM	ProKidney Reports Second Quarter Financial Results and Recent Corporate Highlights (GlobeNewswire)
Jul-18-23 06:05AM	ProKidney Announces Closing of Purchase of Manufacturing Facility in Greensboro, NC (GlobeNewswire)
Jul-17-23 06:05AM	ProKidney Appoints Bruce Culleton, MD, as Executive Vice President, Clinical Development and Commercialization (GlobeNewswire) +6.65%
Jun-13-23 12:05PM	ProKidney Announces Purchase of Manufacturing Facility in Greensboro, NC (GlobeNewswire)
Jun-01-23 04:05PM	ProKidney to Participate in Fireside Chat at the Jefferies Healthcare Conference (GlobeNewswire) -7.66%
May-11-23 04:01PM	ProKidney Reports First Quarter Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-04-23 06:05AM	ProKidney to Present at the BofA Securities Health Care Conference 2023 (GlobeNewswire)
Apr-25-23 02:00PM	We're Interested To See How ProKidney (NASDAQ:PROK) Uses Its Cash Hoard To Grow (Simply Wall St.) -8.73%
Mar-28-23 04:12PM	ProKidney Reports Fourth Quarter Financial Results and Recent Corporate Highlights (GlobeNewswire) -7.39%
Mar-03-23 06:05AM	ProKidney to Participate in TD Cowens 43rd Annual Health Care Conference (GlobeNewswire)
Jan-11-23 07:48AM	ProKidneys stock jumps 29% (MarketWatch)
Jan-10-23 04:05PM	ProKidney Announces Publication of Trial Design for Phase 2 Multicenter Clinical Trial of REACT for Late Stage 4 Diabetes-Related Chronic Kidney Disease (GlobeNewswire) +9.57%
Dec-27-22 11:05AM	Chamath Palihapitiya Stocks: 10 Stocks Picked in the Last 10 Years (Insider Monkey) -5.82%
08:46AM	A Look At The Intrinsic Value Of ProKidney Corp. (NASDAQ:PROK) (Simply Wall St.)
Dec-22-22 06:05AM	ProKidney to Present at the J.P. Morgan 41st Annual Healthcare Conference (GlobeNewswire)
Nov-16-22 11:22AM	ProKidney (NASDAQ:PROK) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Nov-14-22 06:05AM	ProKidney Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Nov-11-22 04:05PM	ProKidney to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.85%
Nov-03-22 06:05AM	ProKidney Receives Allowance from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for proact 1 (REGEN-006) and EMA Scientific Advice on Phase 3 Protocols of REACT for Diabetic Chronic Kidney Disease (GlobeNewswire)
Oct-14-22 12:00PM	ProKidney Announces Multiple Abstracts Selected for Presentation at the American Society of Nephrologys Kidney Week 2022 (GlobeNewswire)
Sep-23-22 06:15AM	ProKidney to Present at the Jefferies Cell and Genetic Medicine Summit (GlobeNewswire)
Sep-08-22 06:05AM	ProKidney to Present at the Morgan Stanley 20th Annual Global Healthcare Conference (GlobeNewswire)
Aug-31-22 06:05AM	ProKidney Appoints Glenn Schulman, PharmD, MPH, as Senior Vice President of Investor Relations (GlobeNewswire) +12.28%
Aug-11-22 05:30PM	ProKidney Corp. Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) +7.55%
10:01AM	ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox (GlobeNewswire)
Jul-20-22 08:00AM	ProKidney Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs (GlobeNewswire)

ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease, shifting the emphasis away from management of kidney failure to the restoration of kidney function to stop or delay progression of CKD. It offers REACT, a product candidate that includes selected renal cells prepared from a patient's own, autologous, and renal cells. The company was founded on December 21, 2015 and is headquartered in Winston-Salem, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Weber Darin J.	Chief Regulatory Officer	Jul 08 '25	Sale	3.02	103,480	312,510	0	Jul 09 04:28 PM
DARIN J WEBER	Officer	Jul 08 '25	Proposed Sale	0.61	103,480	62,761		Jul 08 04:20 PM
Control Empresarial de Capital	Add'l Rep. Persons-see Ex.99-1	Apr 22 '25	Buy	0.71	387,393	276,366	73,842,723	Apr 24 04:15 PM
Control Empresarial de Capital	Add'l Rep. Persons-see Ex.99-1	Apr 17 '25	Buy	0.75	25,000	18,690	73,455,330	Apr 21 04:37 PM
Control Empresarial de Capital	Add'l Rep. Persons-see Ex.99-1	Apr 16 '25	Buy	0.75	100,000	74,820	73,430,330	Apr 18 04:15 PM
Control Empresarial de Capital	Add'l Rep. Persons-see Ex.99-1	Apr 15 '25	Buy	0.70	468,000	326,009	73,330,330	Apr 16 05:04 PM
Control Empresarial de Capital	Add'l Rep. Persons-see Ex.99-1	Apr 14 '25	Buy	0.73	268,105	194,591	72,862,330	Apr 16 05:04 PM
Control Empresarial de Capital	Add'l Rep. Persons-see Ex.99-1	Apr 10 '25	Buy	0.61	1,032,218	627,692	72,592,325	Apr 14 04:30 PM
Control Empresarial de Capital	Add'l Rep. Persons-see Ex.99-1	Apr 11 '25	Buy	0.61	1,900	1,155	72,594,225	Apr 14 04:30 PM

Open in Screener

RPRX

Royalty Pharma plc

Nov 07 • 04:00PM ET

38.56

-2.22 -5.44 %

Healthcare • Biotechnology • USA • NASD

RPRX Royalty Pharma plc daily Stock Chart

Peers: BIIB REGN VRTX GILD INCY ALNY EXEL NBIX MDGL DKNG

| Held by: VFLO VXF IWR VYM SCHM VHT IWD IHE DGRO FNDA

Index	-	P/E	22.05	EPS (ttm)	1.75	Insider Own	21.19%	Shs Outstand	429.03M	Perf Week	2.72%
Market Cap	22.26B	Forward P/E	8.09	EPS next Y	4.77	Insider Trans	-0.03%	Shs Float	340.69M	Perf Month	6.70%
Enterprise Value	33.47B	PEG	2.47	EPS next Q	1.27	Inst Own	75.59%	Short Float	3.98%	Perf Quarter	6.55%
Income	764.74M	P/S	9.47	EPS this Y	10.42%	Inst Trans	4.60%	Short Ratio	3.41	Perf Half Y	16.32%
Sales	2.35B	P/B	2.58	EPS next Y	4.63%	ROA	4.09%	Short Interest	13.58M	Perf YTD	51.16%
Book/sh	14.95	P/C	23.31	EPS next 5Y	8.92%	ROE	11.51%	52W High	41.24 -6.50%	Perf Year	40.01%
Cash/sh	1.65	P/FCF	8.87	EPS past 3/5Y	8.57% -21.51%	ROIC	5.10%	52W Low	24.05 60.33%	Perf 3Y	-8.78%
Dividend Est.	0.93 (2.40%)	EV/EBITDA	21.83	Sales past 3/5Y	-0.38% 4.52%	Gross Margin	-	Volatility	5.30% 2.79%	Perf 5Y	2.61%
Dividend TTM	0.87 (2.26%)	EV/Sales	14.24	EPS Y/Y TTM	-31.46%	Oper. Margin	65.19%	ATR (14)	1.19	Perf 10Y	-
Dividend Ex-Date	Nov 14, 2025	Quick Ratio	3.48	Sales Y/Y TTM	3.72%	Profit Margin	32.54%	RSI (14)	57.29	Recom	1.40
Dividend Gr. 3/5Y	7.30% -	Current Ratio	3.48	EPS Q/Q	-45.18%	SMA20	3.41%	Beta	0.44	Target Price	46.43
Payout	43.94%	Debt/Eq	1.40	Sales Q/Q	7.90%	SMA50	5.65%	Rel Volume	2.34	Prev Close	40.78
Employees	99	LT Debt/Eq	1.34	Earnings	Nov 05 BMO	SMA200	11.68%	Avg Volume	3.98M	Price	38.56
IPO	Jun 16, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-48.24% 13.47%	Trades		Volume	9,328,111	Change	-5.44%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-30-25	Initiated	Goldman	Buy	$42
May-16-25	Initiated	Morgan Stanley	Overweight	$51
Jun-03-24	Downgrade	UBS	Buy → Neutral	$28
Jun-14-22	Resumed	UBS	Buy	$47
May-13-22	Initiated	Scotiabank	Sector Outperform	$53
Apr-27-22	Initiated	Goldman	Buy	$56
Apr-14-22	Upgrade	JP Morgan	Neutral → Overweight	$50
Apr-06-22	Resumed	Morgan Stanley	Overweight	$48
Oct-29-21	Upgrade	Citigroup	Neutral → Buy	$50
Jul-30-21	Initiated	Tigress Financial	Buy	$50
Nov-09-20	Upgrade	UBS	Neutral → Buy	$52 → $51
Jul-14-20	Initiated	Evercore ISI	In-line
Jul-13-20	Initiated	UBS	Neutral	$52
Jul-13-20	Initiated	SunTrust	Buy	$56
Jul-13-20	Initiated	Morgan Stanley	Equal-Weight	$51
Jul-13-20	Initiated	JP Morgan	Neutral	$50
Jul-13-20	Initiated	Goldman	Neutral	$47
Jul-13-20	Initiated	Cowen	Outperform	$55
Jul-13-20	Initiated	Citigroup	Neutral	$50
Jul-13-20	Initiated	BofA Securities	Buy	$55

Show Previous Ratings

Nov-05-25 04:49PM	Analyst Report: Royalty Pharma plc (Morningstar Research) +6.82%
02:03PM	Royalty Pharma PLC (RPRX) Q3 2025 Earnings Call Highlights: Strong Portfolio Growth and ... (GuruFocus.com)
09:30AM	Royalty Pharma (RPRX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:25AM	Royalty Pharma (RPRX) Beats Q3 Earnings and Revenue Estimates (Zacks)
07:23AM	Royalty Pharma: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Loading…
07:00AM	Royalty Pharma Reports Third Quarter 2025 Results (GlobeNewswire)
Nov-04-25 07:15AM	Royalty Pharma Acquires Royalty Interest in Alnylam's AMVUTTRA for $310 Million from Blackstone Life Sciences (GlobeNewswire)
Nov-03-25 10:34PM	Spotting Winners: Royalty Pharma (NASDAQ:RPRX) And Branded Pharmaceuticals Stocks In Q2 (StockStory)
10:15PM	What To Expect From Royalty Pharma's (RPRX) Q3 Earnings (StockStory)
Oct-31-25 12:41PM	How Royalty Pharma Prints Cash Without Biotech's Biggest Risks (MarketBeat)
Oct-29-25 10:00AM	Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy? (Zacks)
12:02AM	2 Reasons to Avoid RPRX and 1 Stock to Buy Instead (StockStory)
Oct-28-25 01:34PM	1 Trial, 2 Franchises: Zenas Stock Climbs on Landmark Data (MarketBeat)
12:24PM	What Do Analysts Think About Royalty Pharma Plc (RPRX)? (Insider Monkey)
Oct-17-25 09:10AM	Praxis Precision Medicines (PRAX) Surges 183.7%: Is This an Indication of Further Gains? (Zacks)
08:15AM	Loading…
08:15AM	Royalty Pharma Declares Fourth Quarter 2025 Dividend (GlobeNewswire)
Oct-14-25 07:45AM	Kailera nets $600M more to advance Zepbound-like obesity drug (BioPharma Dive)
Oct-09-25 04:15PM	Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025 (GlobeNewswire)
Oct-08-25 12:10PM	Will Royalty Pharma (RPRX) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Oct-06-25 08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
Oct-03-25 08:50AM	How to Find Strong Medical Stocks Slated for Positive Earnings Surprises (Zacks)
Sep-29-25 08:15AM	Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director (GlobeNewswire)
Sep-23-25 07:10PM	Royalty Pharma plc (RPRX) Completes $2B Senior Notes Offering, Strengthens Capital for Growth (Insider Monkey)
Sep-19-25 04:25PM	Royalty Pharma to Present at Bernstein's 2nd Annual Healthcare Forum (GlobeNewswire)
Sep-17-25 02:27PM	TD Cowen Maintains a Buy on Royalty Pharma (RPRX) (Insider Monkey)
12:43AM	1 Safe-and-Steady Stock with Promising Prospects and 2 We Ignore (StockStory)
Sep-16-25 09:28AM	Royalty Pharma plc (RPRX) Reports 20% Portfolio Growth, Posts $727M in Q2 Receipts (Insider Monkey)
Sep-11-25 11:13AM	Royalty Pharma plc (RPRX) Commits $300M to Zenas' Obexelimab Program (Insider Monkey)
07:00AM	Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company's Plans to Drive Value Creation (GlobeNewswire)
Sep-10-25 07:30AM	Royalty Pharma Announces Release of Deloitte's Report on the Biopharma Royalty Market (GlobeNewswire)
04:15PM	Loading…
Sep-04-25 04:15PM	Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference (GlobeNewswire)
Sep-02-25 08:30PM	Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes (GlobeNewswire)
07:15AM	Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million (GlobeNewswire)
Aug-29-25 02:57PM	Royalty Pharma (RPRX) Strengthens Pipeline With New Oncology Royalty Purchase (Insider Monkey)
05:05AM	Royalty Pharma plc (RPRX) Boosts Growth with $885M Amgen Imdelltra Royalty Deal (Insider Monkey)
04:54AM	Royalty Pharma plc (RPRX) Strikes $2B Partnership with Revolution Medicines (Insider Monkey)
Aug-25-25 01:19PM	BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up (Benzinga)
08:29AM	Royalty Pharma buys BeOne stake in Amgen lung cancer drug sales (BioPharma Dive)
06:33AM	Royalty Pharma to pay up to $950 million for royalties from Amgen's lung cancer drug (Reuters)
06:10AM	Royalty Pharma to Acquire Royalty Interest in Amgen's Imdelltra for up to $950 Million (GlobeNewswire)
06:00AM	BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million (Business Wire)
Aug-13-25 04:15PM	Henry Fernandez Steps Down from Royalty Pharma's Board of Directors (GlobeNewswire)
01:35AM	5 Insightful Analyst Questions From Royalty Pharma's Q2 Earnings Call (StockStory)
Aug-12-25 09:10AM	Morgan Stanley Maintains a Buy Rating on Royalty Pharma Plc (RPRX) With a $55 PT (Insider Monkey)
03:18AM	RPRX Q2 Deep Dive: Margins Compress Despite Solid Royalty Growth and Strategic Investments (StockStory)
Aug-10-25 11:31PM	Reflecting On Branded Pharmaceuticals Stocks' Q2 Earnings: Royalty Pharma (NASDAQ:RPRX) (StockStory)
Aug-06-25 05:45PM	Analyst Report: Royalty Pharma plc (Morningstar Research)
04:02PM	Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress (GlobeNewswire)
09:30AM	Here's What Key Metrics Tell Us About Royalty Pharma (RPRX) Q2 Earnings (Zacks)
08:20AM	Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates (Zacks)
08:08AM	Royalty Pharma (NASDAQ:RPRX) Misses Q2 Revenue Estimates (StockStory)
07:22AM	Royalty Pharma: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Royalty Pharma Reports Second Quarter 2025 Results (GlobeNewswire)
Aug-05-25 09:15AM	Countdown to Royalty Pharma (RPRX) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS (Zacks)
Aug-04-25 11:21PM	Earnings To Watch: Royalty Pharma (RPRX) Reports Q2 Results Tomorrow (StockStory)
Jul-30-25 10:00AM	Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy? (Zacks)
12:02AM	2 Reasons to Watch RPRX and 1 to Stay Cautious (StockStory)
Jul-18-25 08:15AM	Royalty Pharma Declares Third Quarter 2025 Dividend (GlobeNewswire)
Jul-17-25 08:15AM	Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company's Board of Directors (GlobeNewswire)
Jul-16-25 04:15PM	Royalty Pharma to Announce Second Quarter 2025 Financial Results on August 6, 2025 (GlobeNewswire)
Jul-01-25 06:20AM	Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)? (Zacks)
Jun-27-25 08:33AM	5 Revealing Analyst Questions From Royalty Pharma's Q1 Earnings Call (StockStory)
Jun-24-25 07:05AM	Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion (GlobeNewswire)
Jun-18-25 11:39PM	Q1 Rundown: Royalty Pharma (NASDAQ:RPRX) Vs Other Branded Pharmaceuticals Stocks (StockStory)
Jun-12-25 07:26PM	Analyst Report: Royalty Pharma plc (Morningstar Research)
Jun-09-25 09:54AM	RPRX Q1 Earnings Call: Flat Revenue, Portfolio Expansion, and Capital Return Initiatives (StockStory)
Jun-04-25 04:15PM	Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
May-16-25 04:30PM	Royalty Pharma Completes the Acquisition of Its External Manager (GlobeNewswire)
May-13-25 08:15AM	Royalty Pharma to Present at Upcoming Investor Conferences (GlobeNewswire)
May-12-25 04:15PM	Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition (GlobeNewswire)
May-08-25 08:03PM	Analyst Report: Royalty Pharma plc (Morningstar Research)
10:30AM	Royalty Pharma (RPRX) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
08:25AM	Royalty Pharma (RPRX) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
07:15AM	Royalty Pharma Reports First Quarter 2025 Results (GlobeNewswire)
May-07-25 12:34PM	Royalty Pharma Q1 2025 Earnings Preview (Seeking Alpha)
May-05-25 09:15AM	Unlocking Q1 Potential of Royalty Pharma (RPRX): Exploring Wall Street Estimates for Key Metrics (Zacks)
May-01-25 10:01AM	Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Apr-28-25 06:50PM	Alerus (ALRS) Q1 Earnings and Revenues Top Estimates (Zacks)
Apr-24-25 08:16AM	Royalty Pharma PLC (RPRX) Surged Following an Acquisition Announcement (Insider Monkey)
07:36AM	Thomas: Fragile is the word we agreed on (CNBC TV)
Apr-22-25 12:00PM	Patient Capital Management Q1 2025 Investment Review (Seeking Alpha)
11:20AM	Patient Capital Management Q1 2025 Commentary (Seeking Alpha)
Apr-21-25 04:15PM	Royalty Pharma Declares Second Quarter 2025 Dividend (GlobeNewswire)
Apr-17-25 04:15PM	Royalty Pharma to Announce First Quarter 2025 Financial Results on May 8, 2025 (GlobeNewswire)
Apr-10-25 06:20AM	Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now? (Zacks)
Apr-08-25 04:15PM	Royalty Pharma Appoints Vlad Coric, M.D. to the Company's Board of Directors (GlobeNewswire)
Apr-02-25 09:47AM	Is Royalty Pharma plc (RPRX) The Most Profitable Biotech Stock To Buy Right Now? (Insider Monkey)
Apr-01-25 10:00AM	Is Royalty Pharma Plc (RPRX) the Most Undervalued Healthcare Stock to Buy According to Analysts? (Insider Monkey)
06:20AM	Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)? (Zacks)
Mar-29-25 07:15AM	4 Healthcare Stocks With Massive Gains-and More to Come (MarketBeat)
Mar-27-25 08:15AM	Royalty Pharma Announces Upcoming Investor Day (GlobeNewswire)
Mar-26-25 11:43AM	3 Reasons to Sell RPRX and 1 Stock to Buy Instead (StockStory) -6.52%
Mar-25-25 09:19PM	Is Royalty Pharma plc (RPRX) The Best Defensive Stock Amid Market Volatility? (Insider Monkey)
Mar-21-25 11:30AM	Why Is Blue Owl Capital Corporation (OBDC) Down 3% Since Last Earnings Report? (Zacks)
05:12AM	Q4 Earnings Highs And Lows: Royalty Pharma (NASDAQ:RPRX) Vs The Rest Of The Branded Pharmaceuticals Stocks (StockStory)
Feb-27-25 04:15PM	Royalty Pharma to Present at TD Cowen's 45th Annual Health Care Conference (GlobeNewswire)
Feb-23-25 03:03PM	Why Royalty Pharma Plc (RPRX) is the Best Performing Pharma Stock So Far in 2025 (Insider Monkey)
Feb-13-25 07:57PM	Analyst Report: Royalty Pharma plc (Morningstar Research)
Feb-12-25 09:06AM	Analyst Report: Royalty Pharma plc (Morningstar Research)
06:30AM	Royalty Pharma Announces R&D Funding Collaboration With Biogen (GlobeNewswire)

Royalty Pharma Plc engages in the provision of drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Norden Gregory	Director	Aug 11 '25	Sale	36.23	33,500	1,213,749	194,848	Aug 11 04:35 PM
Norden Gregory	Director	Aug 11 '25	Proposed Sale	36.23	33,500	1,213,747		Aug 11 04:18 PM

PROK

ProKidney Corp

RPRX

Royalty Pharma plc

Upgrade your FINVIZ experience